Evaluation of Neutrophil–Lymphocyte Ratio, Platelet–Lymphocyte Ratio and Red Blood Cell Distribution Width–Platelet Ratio for Diagnosis of Premature Ovarian Insufficiency

Gulsah Ilhan; M.D. 1, Fatma Ferda Verit Atmaca; M.D. 1, Esra Altan; M.D. 1, Ali Galip Zebitay; M.D. 1, Hamdullah Sozen; M.D. 1, Hurkan Akyol; M.D. 1, Meryem Kurek Eken; M.D. 2

1 Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology and Infertility, Suleymaniye Research and Education Hospital, Istanbul, Turkey
2 Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology and Infertility, Adnan Menderes University, Aydin, Turkey

Received August 2016; Revised and accepted November 2016

Abstract
Objective: To evaluate whether systemic inflammatory markers (neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR) and red blood cell distribution width (RDW) to platelet ratio (RPR)) can be used as reliable markers for the diagnosis of premature ovarian insufficiency (POI) and to determine if there is a relationship between these markers and follicle stimulating hormone (FSH), Anti-Müllerian Hormone (AMH) levels.

Materials and methods: Written and electronic medical records were reviewed using searches for diagnoses with the terms of 'premature ovarian failure', 'premature ovarian insufficiency'. Patients younger than the age of 40 were diagnosed to have premature ovarian insufficiency based on their menstrual history and sonographic examination and they were compared with healthy females. Complete blood counts, day-3 hormone profiles, AMH levels of all subjects were analyzed.

Results: NLR was statistically higher in POI group compared with controls ($p < 0.05$). NLR had a positive correlation between FSH ($r = 0.23$, $p = 0.045$) and a negative association with AMH ($r = -0.27$, $p = 0.018$). The area under ROC curve for NLR in POI was 0.66, with a threshold value 1.5 and sensitivity = 75.7 % and specificity = 46.0 %.

Conclusion: NLR can be a marker for the diagnosis of POI. There is a close relationship between NLR and ovarian reserve markers such as FSH and AMH.

Keywords: Inflammation Marker; Premature Ovarian Insufficiency

Introduction
Premature ovarian insufficiency (POI) is an enigmatic condition which is still not completely understood. POI is also called primary ovarian failure and affects 1% of women under the age of 40 years (1, 2). The disease can result from ovarian dysgenesis, follicle growth arrest, premature depletion of the follicle pool or follicular atresia. In patients with POI, ovarian histological features are very similar to those found in post-menopausal ovaries resulting from the natural process of follicular atresia (3).

POI is a term to define the women younger than
40 years of age who present with at least a four-month history of amenorrhea and hypergonadotropic serum profile (follicle stimulating hormone (FSH) levels ≥ 40 mIU per milliliter) (4–8). A diverse etiology for POI has been postulated. Although infectious agents, pelvic surgery, chemotherapy, autoimmune disease, genetic problems, environmental factors may lead to POI, a majority of cases are idiopathic (9).

POI is characterized by sex steroid deficiency (1). It is well established that estrogens influence inflammatory and immune processes. Antiinflammatory activity of estrogen is executed by inhibiting many proinflammatory pathways of innate immunity, adaptive immunity, and inflammatory tissue responses. Decrease of estrogen level leads to a shift towards to a proinflammatory direction (10).

Neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR) and red blood cell distribution width (RDW) to platelet ratio (RPR) correlate with the markers of pro-inflammatory state that are widely known as the hematological markers of systemic inflammation. NLR was shown to be elevated in miscellaneous diseases and has been widely used to determine the severity of inflammation (11-18). PLR was found to be an independent risk factor of reduced survival in patients with various kinds of malignancies (19-22). RPR was concluded as a valuable, novel laboratory test to predict mortality in various diseases (23, 24).

Current studies have failed to determine specific biomarkers of POI. We also have limited tool for diagnosis. It is hypothesized that estrogen defiency in POI patients leads to a shift towards to an inflammatory direction and widely known markers of systemic inflammation including NLR, PLR and RPR might be affected.

The aims of this study were to evaluate whether inflammatory markers can be used as reliable markers for diagnosis of POI and to determine if there is any relationship between these markers and ovarian reserve markers such as FSH, Anti-Müllarian Hormone (AMH) levels.

Materials and methods

We conducted a retrospective study to analyze women presenting with POI. This study was carried out at Suleymaniye Maternity and Women’s Disease Education and Research Hospital, In Vitro Fertilization clinic, Istanbul, Turkey. Written and electronic medical records between January 2013 and February 2016 were reviewed using searches for diagnoses with the terms of 'premature ovarian failure', 'premature ovarian insufficiency'. All procedures performed in studies involving human participants were in accordance with the ethical standards of institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

The study was approved by local ethics committee. (the ethical code number: 87534341/846).

37 patients with POI (Group A) and 37 healthy females (Group B) were included. Patients younger than the age of 40 were diagnosed to have premature ovarian insufficiency based on their menstrual history (at least a 4-month history of amenorrhea), gonadotropins levels (follicle stimulating hormone (FSH) levels ≥ 40 mIU per milliliter) and sonographic examination (TOSHIBA EXPERT 5 MHz) (no or a few demonstrable follicles on transvaginal ultrasound) were included in this study. All POI patients had a normal female 46,XX karyotype.

Secondary causes of amenorrhea including pregnancy, polycystic ovarian syndrome, chronic medical illness(uncontrolled diabetes mellitus or celiac disease), hypothalamic amenorrhea, extreme exercise, poor caloric intake, hyperprolactinemia, hyperthyroidism, hypothalamic or pituitary lesions, women with histories of chemotherapy, pelvic surgery, radiation exposure or premature ovarian insufficiency due to extensive ovarian surgery were excluded. Medical conditions that may interfere with complete blood count parameters including hematologic, cardiovascular, kidney-liver disease, asthma, arthritis, neoplastic disease such as androgen-secreting tumours, ovarian tumour, use of glucocorticoids, infectious and parasitic diseases were also excluded.

Complete blood counts, day-3 hormone profiles, AMH levels of all subjects were analyzed. NLR, PLR and RPR were calculated for both the patients and the control group. The complete blood count was performed using an auto haematology analyser (BC-6800, Mindray). Plasma levels of FSH were measured by conventional radioimmunoassay (Immunotech Beckman, France) and AMH was measured by ELISA (Enzyme-Linked ImmunoSorbent Assay) (Beckman Coulter-Inc.).

In statistical analysis, SPSS 17.0 for windows package program was used. Mean and standard deviation values of parameters were used to describe scale variables. Kolmogorov Smirnov test was used...
to define normality of parameters. Independent Samples T-test was used for normally distributed parameters. Mann Whitney U test was used for nonparametric values (Neutrophile, RDW and FSH). Pearson's correlation test was used for correlation between variables, and linear regression was used to analyze estimated model. ROC analysis was used for determination of predictive value of NLR. Difference analysis was performed at 95% Confident Interval and correlation analysis was performed at 95-99% Confident Interval.

p < 0.05 was considered statistically significant.

Results

A total of 37 patients meeting the strict inclusion and exclusion criteria were included in Group A and 37 healthy subjects were included in Group B. Baseline characteristics of both groups were shown in Table 1. There were no differences in terms of age, neutrophile, lymphocyte, platelet count, and RDW (p > 0.05, for all). However, FSH levels were significantly higher and AMH levels were lower in POI group (p < 0.0001, for all) (Table 1).

Although there were no statistically significant differences on neutrophile and lymphocyte counts, NLR showed statistically significant difference between groups (p < 0.05) (Table 2).

The correlation between NLR and ovarian reserve markers such as FSH and AMH were also analyzed. NLR had a positive correlation between FSH (r = 0.23, p = 0.045) and a negative association with AMH (r = -0.27, p = 0.018). However, linear regression analysis found that FSH and AMH levels were not independent variables that were associated with NLR (p > 0.05, for both). We also performed ROC curve analysis for NLR in POI group that was shown in Figure 1. The area under ROC curve for NLR in POI was 0.66, with a threshold value 1.5 and sensitivity = 75.7 % and specificity = 46.0 %.

Discussion

In the present study, we found that only NLR, but not PLR or RPR was statistically higher in POI group compared with controls. There was a close relationship between NLR and ovarian reserve markers such as FSH and AMH. Furthermore, ROC analysis showed that NLR may be considered a marker for the diagnosis of POI.

It is knowned that estrogens influence inflammatory and immune processes. It has been shown that important proinflammatory pathways such as TNF, IL-1, IL-6, MCP-1, iNOS expression, production of MMPs, and activity of natural killer cells and reactive oxygen species formation are inhibited and antinflammatory pathways such as IL-4, IL-10, TGF, TIMP, osteoprotegerin are stimulated by estrogen (10).

Some immunological alterations have been expressed in POI patients. For instance; organ specific autoantibodies can be detected up to 20% of POI cases (25).

Table 1: Baseline characteristics of patient and control groups

| Parameters (Mean ± SD) | Group A (n = 37) | Group B (n = 37) | p     |
|------------------------|-----------------|-----------------|-------|
| Age (year)             | 33.38 ± 4.61    | 31.81 ± 3.76    | 0.113 |
| Neutrophile count (10e3/uL) | 4.13 ± 1.17    | 3.75 ± 1.30    | 0.051 |
| Lymphocyte count (10e3/uL) | 2.03 ± 0.67    | 2.24 ± 0.62    | 0.167 |
| Platelet count (10e3/uL) | 254.70 ± 51.78 | 267.81 ± 63.15 | 0.332 |
| RDW (%)                | 41.61 ± 3.07    | 42.69 ± 4.20    | 0.239 |
| FSH (mIU/ml)           | 54.46 ± 16.89   | 7.19 ± 1.29     | < 0.001 |
| AMH (ng/ml)            | 0.410 ± 0.43    | 1.45 ± 0.29     | < 0.001 |

AMH: Anti-müllerian Hormone, FSH: Follicle stimulating hormone, RDW: Red cell distribution width.

*aIndependent Samples T-test; bMann Whitney-U test
Table 2: Blood parameters of patient and control groups

| Parameters (Mean ± SD) | Group A (n = 37) | Group B (n = 37) | p     |
|-----------------------|------------------|------------------|-------|
| NLR                   | 2.20 ± 0.81      | 1.76 ± 0.64      | 0.011*|
| PLR                   | 138.07 ± 51.35   | 125.71 ± 33.95   | 0.226*|
| RPR                   | 0.17 ± 0.04      | 0.17 ± 0.05      | 0.880*|

NLR: neutrophil to lymphocyte ratio, PLR: platelet to lymphocyte ratio, RPR: red blood cell distribution width to platelet ratio; * Independent Samples T-test

Alteration in cellular immunity such as macrophage and dendrite cells abnormalities, change in CD4+/CD8+ ratio, as well as inappropriate expression of class II MHC antigens by granulosa cells have been seen (26).

NLR, PLR and RPR correlate with the markers of pro-inflammatory state that are widely known as the hematological markers of systemic inflammation. NLR has been widely used to determine the severity of inflammation (11-18). Up to date, it has been shown that diabetes mellitus, thyroid functional abnormalities, renal failure, essential hypertension, metabolic syndrome, valvular heart diseases, acute pancreatitis in pregnancy, cardiovascular disease, autoinflammatory diseases and malignancies including renal cell cancer, ovarian, lung, gastric and colorectal cancer may potentially affect the NLR (11-22). PLR was found to be an independent risk factor of reduced survival in patients with malignancies such as pancreatic and colorectal cancer (19-22). RPR is concluded as a valuable, novel laboratory test to predict mortality in acute pancreatitis, hepatic fibrosis and cirrhosis (23, 24). In our study; we assessed NLR, PLR and RPR as the predictors of disease in women with POI. We found that NLR showed statistically significant difference between groups, but the others not. ROC analysis showed that NLR can be a marker for the diagnosis of POI.

AMH is a member of TGF-B (transforming growth factor-B) family. It is an important ovarian aging test for the evaluation of follicular pool and has a strong correlation with antral follicle count (27, 28). It is now widely considered the best laboratory test to represent total ovarian reserve (29-35). According to the results of the study conducted by Alipour et al (36), AMH serum level is more sensitive than FSH serum level in early diagnosis of POI. Also AMH has more negative predictive value. AMH is reported to be more useful in early diagnosis of POI. In our study; although there were statistically significant correlations between NLR and FSH and AMH, according to regression analysis, FSH and AMH levels are individually not predictors of NLR.

However, a new predictor of the disease is defined in the present study, this study has some limitations. It has a retrospective design and only represents experience of a single institution. Case group is small in number and the etiology is purely idiopathic. It is a hospital based study, so this study can not reflect all population. The results should be confirmed with larger groups. Retrospective design of the study did not allow to assess other systemic inflammatory markers including ILs, CRP and TNF-α. On the other hand, the systemic inflammatory response measured using the NLR, PLR and RPR has been proposed to be an inexpensive, widely available and reproducible way. Easier and these kind of cheaper tests will improve its use in clinical practice.

In conclusion, the main aim of our study is to identify a novel marker for POI and to have an idea about the relation of this marker with ovarian reserve markers such as FSH and AMH in this group. We claimed that NLR may be used as a marker of POI. The low cost, easy accessibility and reproducibility of a NLR may promote its use in clinical practice. Further larger randomized controlled trials are needed for routine use in the future.

Conflict of Interests
Authors have no conflict of interests.

Acknowledgments
We thank to Mr. Roger Manners for English edition.

References
1. Jewelwicz R, Schwartz M. Premature ovarian failure. Bull N Y Acad Med 1986;62:219-36.
2. Laughlin D, ThorneyCroft IH. Amenorrhea. In: Decherne AH, Nathan LI, eds. Current Obstetric & Gynecologic Diagnosis & Treatment. 9th ed. New York: McGraw-Hill; 2003: 991-1000.
3. Board JA, Redwine FO, Moncure CW, Frable WJ,
Taylor JR. Identification of differing etiologies of clinically diagnosed premature menopause. Am J Obstet Gynecol 1979; 134:936-44.

4. Pal L, Santoro N. Premature ovarian failure (POF): discordance between somatic and reproductive aging. Ageing Res Rev 2002;1:413-23.

5. Rees M, Purdie D. Premature menopause. In: Rees M, Purdie D, editors. Management of the menopause: the handbook. London: Royal Society of Medicine Press Ltd;2006; 142-49.

6. Nelson LM. Clinical practice. Primary ovarian insufficiency. N Engl J Med 2009;360:606-14.

7. Khole V. Does ovarian autoimmunity play a role in the pathophysiology of premature ovarian insufficiency? J Midlife Health 2010;1:9-13.

8. Ebrahimi M, Akbari Ashbagh F. Pathogenesis and causes of premature ovarian failure: An update. Int J Fertil Steril 2011;5:54-65.

9. Matzuk MM, Lamb DJ. The biology of infertility: research advances and clinical challenges. Nat Med 2008;14:1197–213.

10. Straub RH. The complex role of estrogens in inflammation. Endocr Rev 2007;28:521–74.

11. Yamanaka T, Matsumoto S, Teramukai S, Iishiwata R, Nagai Y, Fukushima M. The baseline ratio of neutrophils to lymphocytes is associated with patient prognosis in advanced gastric cancer. Oncology 2007;73:215–20.

12. Cho H, Hur HW, Kim SW, Kim SH, Kim JH, Kim YT, Lee K. Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment. Cancer Immunol Immunother 2009;58:15–23.

13. Azab B, Jaglall N, Atallah JP, Lamet A, Raja-Surya V, Farah B, et al. Neutrophil-lymphocyte ratio as a predictor of adverse outcomes of acute pancreatitis. Pancreatology 2011;11:445–52.

14. Guthrie GJ, Charles KA, Roxburgh CS, Horgan PG, McMillan DC, Clarke SJ. The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. Crit Rev Oncol Hematol 2013;88:218–30.

15. Stotz M, Gerger A, Eisner F, Szkandera J, Loibner H, Ress AL, et al. Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer. Br J Cancer 2013;109:416–21.

16. Zheng YB, Zhao W, Liu B, Lu LG, He X, Huang JW, et al. The blood neutrophil to lymphocyte ratio predicts survival in patients with advanced hepatocellular carcinoma receiving sorafenib. Asian Pac J Cancer Prev 2013;14:5527–31.

17. Tanoglu A, Karagoz E. Predictive role of neutrophil to lymphocyte ratio in patients with advanced hepatocellular carcinoma receiving sorafenib. Asian Pac J Cancer Prev 2014;15:1063.

18. Ilhan M, Ilhan G, Gök AF, Bademli S, Verit Atmaca F, Ertekin C. Evaluation of neutrophil-lymphocyte ratio, platelet-lymphocyte ratio and red blood cell distribution width-platelet ratio as early predictor of acute pancreatitis in pregnancy. J Matern Fetal Neonatal Med 2016;29:1476-80.

19. Betterle C, Volpato M, Rees Smith B, Furmaniak J, Chen S, Greggio NA, et al. I. Adrenal cortex and steroid 21-hydroxylase autoantibodies in adult patients with organ-specific autoimmune diseases: markers of low progression to clinical Addison’s disease. J Clin Endocrinol Metab 1997;82:932–8.

20. van Der Vooro DJ, van Der Weijer PH, Barentsen R. Early menopause: increased fracture risk at older age. Osteoporos Int 2003;14:525–30.

21. Schmidt PJ, Cardoso GM, Ross JL, Haq N, Rubinow DR, Bondy CA. Shyness, social anxiety, and impaired self-esteem in Turner syndrome and premature ovarian failure. JAMA 2006;295:1374–6.

22. Shuster LT, Rhodes DJ, Gostout BS, Grossardt BR, Rocca WA. Premature menopause or early menopause: long-term health consequences. Maturitas 2010;65:161–6.

23. Chen B, Ye B, Zhang J, Ying L, Chen Y. RDW to platelet ratio: a novel noninvasive index for predicting hepatic fibrosis and cirrhosis in chronic hepatitis B. PLoS ONE 2013;8:e68780.

24. Cetinkaya E, Senol K, Saylam B, Tez M. Red cell distribution width to platelet ratio: new and promising prognostic marker in acute pancreatitis. World J Gastroenterol 2014;20:14450–4.

25. Forges T, Monnier-Barbarino P, Faure GC, Bene MC. Autoimmunity and antigenic targets in ovarian pathology. Hum Reprod Update 2004;10:163–75.

26. Yan G, Schoenfeld D, Penney C, Hurxthal K, Taylor AE, Faustman D. Identification of premature ovarian failure patients underlying autoimmunity. J Womens Health Gend Based Med 2000;9:275-87.

27. Mutlu MF, Erdem A. Evaluation of ovarian reserve in infertile patients. J Turk Ger Gynecol Assoc 2012;13:196–203.

28. Gökşedef BP, İdüş N, Görgen H, Rüstemoğlu Asma Y, Api M, Çetin A. The correlation of the antral follicle count and serum anti-mullerian hormone. J Turk Ger Gynecol Assoc 2010;11:212–5.

29. Ledger WL. Clinical utility of measurement of anti-
mullerian hormone in reproductive endocrinology. J Clin Endocrinol Metab 2010;95:5144–54.
30. Michels AW, Gottlieb PA. Autoimmune polyglandular syndromes. Nat Rev Endocrinol 2010;6:270–7.
31. Gleicher N, Weghofer A, Barad DH. The role of androgens in follicle maturation and ovulation induction: friend or foe of infertility treatment? Reprod Biol Endocrinol 2011;9:116.
32. Gleicher N, Weghofer A, Kim A, Barad DH. The impact in older women of ovarian FMR1 genotypes and sub-genotypes on ovarian reserve. PLoS ONE 2012;7:e33638.
33. Nelson SM, Anderson RA, Broekmans FJ, Raine-Fenning N, Fleming R, La Marca A. Anti-Müllerian hormone: clairvoyance or crystal clear? Hum Reprod 2012;27:631–6.
34. Kushnir VA, Himaya E, Barad DH, Weghofer A, Gleicher N. Functional ovarian reserve assessment in young oocyte donors based on FMR1 genotypes and sub-genotypes. Fertil Steril 2013;100:S114.
35. Sen A, Kushnir VA, Barad DH, Gleicher N. Endocrine autoimmune diseases and female infertility. Nat Rev Endocrinol 2014;10:37–50.
36. Alipour F, Rasekhjahromi A, Maalhagh M, Sobhanian S, Hosseinpoor M. Comparison of Specificity and Sensitivity of AMH and FSH in Diagnosis of Premature Ovarian Failure. Dis Markers 2015;2015:585604.

Citation: Ilhan G, Verit Atmaca FF, Altan E, Zebitay AG, Sozen H, Akyol H, et al. Evaluation of Neutrophil–Lymphocyte Ratio, Platelet–Lymphocyte Ratio and Red Blood Cell Distribution Width–Platelet Ratio for Diagnosis of Premature Ovarian Insufficiency. J Fam Reprod Health 2016; 10(4): 211-216.